Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QDEL logo QDEL
Upturn stock ratingUpturn stock rating
QDEL logo

Quidel Corporation (QDEL)

Upturn stock ratingUpturn stock rating
$28.57
Last Close (24-hour delay)
Profit since last BUY-0.38%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: QDEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $43.43

1 Year Target Price $43.43

Analysts Price Target For last 52 week
$43.43 Target price
52w Low $22.05
Current$28.57
52w High $49.45

Analysis of Past Performance

Type Stock
Historic Profit -15.46%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.94B USD
Price to earnings Ratio -
1Y Target Price 43.43
Price to earnings Ratio -
1Y Target Price 43.43
Volume (30-day avg) 8
Beta 0.15
52 Weeks Range 22.05 - 49.45
Updated Date 09/14/2025
52 Weeks Range 22.05 - 49.45
Updated Date 09/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.84

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -17.01%
Operating Margin (TTM) -0.73%

Management Effectiveness

Return on Assets (TTM) 1.36%
Return on Equity (TTM) -15.64%

Valuation

Trailing PE -
Forward PE 8.38
Enterprise Value 4580916313
Price to Sales(TTM) 0.71
Enterprise Value 4580916313
Price to Sales(TTM) 0.71
Enterprise Value to Revenue 1.67
Enterprise Value to EBITDA 21.7
Shares Outstanding 67900496
Shares Floating 62649044
Shares Outstanding 67900496
Shares Floating 62649044
Percent Insiders 0.92
Percent Institutions 117.99

ai summary icon Upturn AI SWOT

Quidel Corporation

stock logo

Company Overview

overview logo History and Background

Quidel Corporation, founded in 1979, develops, manufactures, and markets diagnostic testing solutions for point-of-care and laboratory use. Initially focused on monoclonal antibody technology, it expanded into rapid diagnostic tests and molecular diagnostics through internal development and acquisitions.

business area logo Core Business Areas

  • Rapid Immunoassay: Develops and manufactures rapid diagnostic tests for infectious diseases, cardiac biomarkers, and women's health.
  • Molecular Diagnostics: Offers molecular diagnostic solutions for infectious diseases using real-time PCR technology.
  • Specialty Products: Provides products for autoimmune and complement testing.

leadership logo Leadership and Structure

The company is led by Douglas Bryant (CEO). The organizational structure includes departments for R&D, Manufacturing, Sales & Marketing, and Finance, operating under a board of directors.

Top Products and Market Share

overview logo Key Offerings

  • Sofia 2 Fluorescent Immunoassay Analyzer: A point-of-care diagnostic system for influenza A and B, Strep A, RSV, and other respiratory illnesses. Competitors include Abbott (ABT) ID NOW, Roche (RHHBY) cobas Liat, and BD (BDX) Veritor. Market Share estimated around 10% of the POC market in 2023, but revenue from this product is hard to isolate since different tests can be done.
  • Lyra Direct SARS-CoV-2 Assay: A real-time PCR assay for the detection of SARS-CoV-2. Market share has decreased since the height of the pandemic. Competitors include Roche (RHHBY), Thermo Fisher Scientific (TMO), and Abbott (ABT). Revenue from this product has declined significantly.
  • Triage MeterPro: A cardiovascular and toxicology testing platform for hospital and physician office settings, including B-type natriuretic peptide (BNP) testing. Competitors include Abbott (ABT), Roche (RHHBY), and Siemens Healthineers (SHL). Market share is smaller than the main competitors, but revenue contribution is significant.

Market Dynamics

industry overview logo Industry Overview

The diagnostics industry is characterized by innovation in testing methodologies, increasing demand for point-of-care diagnostics, and regulatory scrutiny. The market is driven by aging populations, the prevalence of infectious diseases, and growing healthcare expenditure.

Positioning

Quidel Corporation is a mid-sized player in the diagnostics market, focusing on rapid and molecular diagnostics. It has a strong presence in point-of-care testing and aims to expand its market share through product innovation and strategic acquisitions.

Total Addressable Market (TAM)

The global in vitro diagnostics market is estimated to be around $90 billion USD. Quidel, as a mid-sized player, is positioned to capture a portion of the TAM through its established product lines and continued expansion into molecular diagnostics.

Upturn SWOT Analysis

Strengths

  • Strong presence in point-of-care diagnostics
  • Established distribution network
  • Innovative product pipeline
  • Proprietary technologies

Weaknesses

  • Reliance on seasonal infectious disease testing (Flu)
  • Smaller scale compared to larger competitors
  • Fluctuating revenue based on pandemic surges
  • Relatively low R&D investment compared to competitors

Opportunities

  • Expanding into new geographic markets
  • Developing new diagnostic tests for emerging diseases
  • Strategic partnerships and acquisitions
  • Growth in molecular diagnostics market

Threats

  • Intense competition from larger diagnostic companies
  • Changing regulatory landscape
  • Economic downturn impacting healthcare spending
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • Abbott Laboratories (ABT)
  • Roche Holding AG (RHHBY)
  • Thermo Fisher Scientific (TMO)

Competitive Landscape

Quidel Corporation is smaller than its main competitors, but it has a strong presence in point-of-care diagnostics. The competitive landscape is characterized by intense competition and continuous innovation.

Major Acquisitions

Ortho Clinical Diagnostics

  • Year: 2022
  • Acquisition Price (USD millions): 6000
  • Strategic Rationale: Expanded product portfolio, broader geographic reach, and increased scale. This acquisition transformed Quidel into a larger, more diversified diagnostics company. Synergies included cross-selling opportunities, cost reductions, and R&D collaborations.

Growth Trajectory and Initiatives

Historical Growth: Historical growth was driven by acquisitions and increasing demand for rapid diagnostic tests, particularly during the COVID-19 pandemic. Post-pandemic growth has slowed significantly.

Future Projections: Analyst estimates suggest a return to moderate growth driven by new product launches and expansion into new markets, with projections of revenue stabilizing and potentially increasing over the next 3 years.

Recent Initiatives: Recent initiatives include the acquisition of Ortho Clinical Diagnostics (OCDX), focusing on synergies between the companies. Also, they are focusing on the development of new multiplex assays and expanding into new therapeutic areas.

Summary

Quidel Corporation has seen significant volatility in recent years. While it had exceptional growth during the COVID-19 pandemic, its revenue and profitability have since declined. The acquisition of Ortho Clinical Diagnostics offers potential for long-term growth, but the company faces significant integration challenges and fierce competition. Future success hinges on its ability to innovate, expand into new markets, and capitalize on synergies from the acquisition.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Analyst Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and analyst estimates, which are subject to change. Market share estimates are approximate and may vary across different sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Quidel Corporation

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 1991-02-01
President, CEO & Director Mr. Brian J. Blaser
Sector Healthcare
Industry Medical Devices
Full time employees 6600
Full time employees 6600

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.